Could Audentes Therapeutics Incorporated (NASDAQ:BOLD) See a Reversal After More Sellers Came In?

September 17, 2017 - By Marie Mckinney

 Could Audentes Therapeutics Incorporated (NASDAQ:BOLD) See a Reversal After More Sellers Came In?

The stock of Audentes Therapeutics Incorporated (NASDAQ:BOLD) registered an increase of 4.74% in short interest. BOLD’s total short interest was 682,200 shares in September as published by FINRA. Its up 4.74% from 651,300 shares, reported previously. With 227,600 shares average volume, it will take short sellers 3 days to cover their BOLD’s short positions. The short interest to Audentes Therapeutics Incorporated’s float is 7.35%.

The stock increased 2.72% or $0.66 on September 15, reaching $24.92. About 196,577 shares traded or 14.84% up from the average. Audentes Therapeutics Inc (NASDAQ:BOLD) has 0.00% since September 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The company has market cap of $692.38 million. The Firm is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. It currently has negative earnings. The Firm has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy ; AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

More notable recent Audentes Therapeutics Inc (NASDAQ:BOLD) news were published by: Prnewswire.com which released: “Audentes Therapeutics Announces Initiation of Large-scale cGMP Production at …” on November 29, 2016, also Prnewswire.com with their article: “Audentes Therapeutics Announces Presentation Of Data From RECENSUS, A Medical …” published on March 20, 2017, Prnewswire.com published: “Audentes Therapeutics Announces FDA Clearance of Investigational New Drug …” on February 01, 2017. More interesting news about Audentes Therapeutics Inc (NASDAQ:BOLD) were released by: Seekingalpha.com and their article: “We’re Not Audacious On Audentes Therapeutics’ IPO” published on July 18, 2016 as well as Prnewswire.com‘s news article titled: “Audentes Therapeutics Reports First Quarter 2017 Financial Results and …” with publication date: May 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.